dendritic cell

(redirected from Plasmacytoid dendritic cell)
Also found in: Medical, Encyclopedia.

dendritic cell

n.
Any of various white blood cells that have long projections from the cell body and function in the immune response by taking in and processing antigens and presenting them to T cells in lymph nodes, thus activating the T cells. Immature dendritic cells are found chiefly in skin and mucosal surfaces.
Translations
célula dendrítica
cellula dendritica
References in periodicals archive ?
The Company informed that investigators will present the following four abstracts on SL-401, a novel targeted therapy directed to the Interleukin-3 Receptor on cancer stem cells (CSCs) and Tumor Bulk, in patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), via poster presentation - an update on the robust clinical activity; Preclinical Studies: Potent Activity in BPDCN Cell Lines, Primary Tumor, and in an In Vivo Model; Possesses Preclinical Cytotoxic Activity against Chronic Eosinophilic Leukemia; and Inhibits Plasmacytoid Dendritic Cell (pDC)-induced Myeloma Cell Growth and Overcomes Drug Resistance.
Using synthetic ligands of TLR9, they concluded that HBV can block plasmacytoid dendritic cell stimulation.
Food and Drug Administration (FDA) for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare and aggressive hematologic malignancy for which there is no effective treatment.
Early plasmacytoid dendritic cell changes predict plasma HIV load rebound during primary infection.
The differential diagnosis of myeloid sarcoma in the head and neck region includes several types of malignant lymphoma (B cell and T cell); blastic plasmacytoid dendritic cell neoplasm; solid tumors, such as carcinoma and melanoma; and small blue cell tumors of childhood.
IgG-nucleic acid complexes, in one form or another, may also stimulate a specialized form of dendritic cell, termed a plasmacytoid dendritic cell, that is believed to be the most important source of IFN.
a clinical-stage biopharmaceutical company developing oncology therapeutics that target both cancer stem cells (CSCs) and tumor bulk, announced today that a second heavily pre-treated patient with a drug-refractory and recurrent blastic plasmacytoid dendritic cell neoplasm (BPDCN) achieved a complete response (CR) following treatment with a single cycle of Stemline's lead therapeutic, SL-401.
today announced that two studies featuring SL-401 updated clinical trial results in acute myeloid leukemia (AML) and other hematologic malignancies, including blastic plasmacytoid dendritic cell neoplasm (BPDCN), and SL-101 preclinical activity against Hodgkin's lymphoma have been selected for presentation at the upcoming 54[sup.
a clinical-stage biopharmaceutical company developing oncology therapeutics that target both cancer stem cells (CSCs) and tumor bulk, announced today that a heavily pre-treated patient with a drug-refractory and recurrent blastic plasmacytoid dendritic cell neoplasm (BPDCN) achieved a complete response (CR) following treatment with Stemline's SL-401.
The other study shows that SL-401 is cytotoxic against primary tumor cells obtained from patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare lymphoma with limited treatment options.
Radstake~s has focused on immune cell subsets, in particular on plasmacytoid dendritic cells (pDCs), to identify their potential role in SSc.